<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071746</url>
  </required_header>
  <id_info>
    <org_study_id>08/HO714/8</org_study_id>
    <nct_id>NCT01071746</nct_id>
  </id_info>
  <brief_title>Predictive Utility of DASIMAR as a Prognostic Biomarker in Acute-on-chronic Liver Failure (ACLF)</brief_title>
  <acronym>DASIMAR</acronym>
  <official_title>The Predictive Utility of the Dimethylarginines and Ischemia Modified Albumin as Prognostic Biomarkers in Patients With Acute-on-chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College London Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute on chronic liver failure have a risk of developing multiorgan failure and&#xD;
      a high mortality. The current scoring systems defining the outcome of patients with acute&#xD;
      decompensation of cirrhosis fail to identify patients that progress to Acute-on-chronic liver&#xD;
      failure (ACLF).&#xD;
&#xD;
      The aim of the study is to evaluate if one can identify these patients early on with the&#xD;
      proposed biomarkers: dimethylarginines and ischemia modified albumin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute-on-chronic liver failure (ACLF) are at risk of multiorgan failure and&#xD;
      high mortality. Recent data suggest that patients with decompensated liver cirrhosis have&#xD;
      higher ADMA (asymmetrical dimethylarginine) levels compared to compensated cirrhosis and&#xD;
      plasma ADMA levels correlate with severity of liver dysfunction and inflammation. There is&#xD;
      also an increase in symmetric dimethylarginine (SDMA), a stereo-isomer of ADMA, which is&#xD;
      largely excreted by the kidney. Plasma SDMA levels have been shown to be associated with&#xD;
      patients&#xD;
&#xD;
      progressing to renal failure. In a pilot study by our group involving 52 patients with acute&#xD;
      decompensation of chronic liver disease, we showed an increase in the summed product of ADMA&#xD;
      and SDMA, which we termed dimethylarginine score ('DAS'): This was shown to have a good&#xD;
      predictive utility for outcome in this small group of patients (AUROC=0.89).&#xD;
&#xD;
      Furthermore, we and others have shown that albumin of patients with advanced liver disease&#xD;
      has widespread abnormalities. The amount of albumin that is found to have reduced metal&#xD;
      binding capacity as a consequence of oxidative damage is termed Ischemia Modified Albumin&#xD;
      (IMA).&#xD;
&#xD;
      Our data shows that patients with ACLF who die have a significantly increased IMA/serum&#xD;
      albumin ratio (IMAR). The summation of these two pathologically relevant biomarkers&#xD;
      (DAS+IMAR) we termed DASIMAR and found this score to have a better predictive utility than&#xD;
      DAS alone (AUROC:0.91).&#xD;
&#xD;
      Primary objective : To identify the patients early on that progress to ACLF which would&#xD;
      facilitate a goal directed therapeutic approach.&#xD;
&#xD;
      Secondary objective : Generation of this dataset will further define and enable&#xD;
      prognostication of ACLF. If this study reveals a role for these biomarkers in patients with&#xD;
      ACLF, commercial development of simple kits may be possible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">November 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progress to ACLF</measure>
    <time_frame>hours, days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognosticate ACLF</measure>
    <time_frame>Days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Acute decompensation of cirrhosis</arm_group_label>
    <description>acute decompensation of liver function occuring secondary to precipitating events such as sepsis, GI bleed.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients with acute clinical deterioration of cirrhosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with an acute clinical decompensation of presumed cirrhosis (elevated&#xD;
             bilirubin &gt;85 Âµmol/L, or/and increasing ascites or/and hepatic encephalopathy &lt; grade&#xD;
             2) related to a clear precipitating event (e.g. infection, bleeding, alcoholic&#xD;
             hepatitis, exposure to hepatotoxin)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Admission for reasons other than decompensation of cirrhosis (other co-morbid&#xD;
             diseases, especially established cardiovascular or renal disease (U/S).&#xD;
&#xD;
          -  Malignancy (extra-hepatic or a hepatocellular carcinoma).&#xD;
&#xD;
          -  Patients who have undergone major surgery or have unsolved surgical problems.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajeshwar P Mookerjee, BScMRCPPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajeshwar P Mookerjee, BScMRCPPhD</last_name>
    <phone>02076796516</phone>
    <email>r.mookerjee@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naina Shah, MBBSMRCP</last_name>
    <phone>02076796516</phone>
    <email>naina.shah@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1E 6HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajeshwar P Mookerjee, BScMRCPPhD</last_name>
      <phone>02076796516</phone>
    </contact>
    <contact_backup>
      <last_name>Naina Shah, MBBSMRCP</last_name>
      <phone>02076796516</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>February 18, 2010</last_update_submitted>
  <last_update_submitted_qc>February 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Rajeshwar P Mookerjee</name_title>
    <organization>University College London Hospitals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

